Familial hypocalciuric hypercalcaemia

Edward M. Brown

in Oxford Textbook of Endocrinology and Diabetes

Second edition

Published on behalf of Oxford University Press

ISBN: 9780199235292
Published online July 2011 | e-ISBN: 9780199608232 | DOI:

Series: Oxford Textbooks

Familial hypocalciuric hypercalcaemia

More Like This

Show all results sharing this subject:

  • Endocrinology and Diabetes


Show Summary Details


Familial hypocalciuric hypercalcaemia (FHH) is a generally asymptomatic form of mild to moderate, parathyroid hormone (PTH)-dependent hypercalcaemia, which was initially confused with the more common hypercalcaemic disorder, primary hyperparathyroidism (PHPT) (1–3). Subsequent studies showed that FHH differs from PHPT in several important respects, although distinguishing between these two conditions can still be difficult on a clinical basis alone (4). Urinary calcium excretion is lower in the former than in the latter, and in FHH, unlike PHPT, hypercalcaemia recurs rapidly following surgical treatment with anything less than total parathyroidectomy. Indeed, given FHH’s generally benign natural history, surgery is usually ill advised (3).

The phenotype of FHH implicated some abnormality in the sensing and/or handling of calcium by parathyroid and kidney (3, 5). For more than two decades after its initial description, however, the genetic defect in FHH was unknown. In 1992, the major genetic locus for this condition was identified on the long arm of chromosome 3 (6). The following year saw the cloning of a G protein-coupled extracellular calcium (Ca2+o)-sensing receptor (CaSR) mediating direct regulation of PTH secretion by Ca2+o (7). The CaSR’s function and its location of its gene on the same region chromosome 3 in humans made it an obvious candidate gene for FHH. Shortly thereafter, heterozygous inactivating mutations in the CaSR were identified in several FHH families (8). Moreover, patients with a related condition, neonatal severe hyperparathyroidism (NSHPT), also turned out to harbour inactivating CaSR mutations in the homozygous, compound heterozygous, and in a milder disorder, neonatal hyperparathyroidism (NHPT), in the heterozygous state (8). This chapter reviews the clinical and biochemical features of FHH, its genetics, pathophysiology, and pathogenesis, and its relationship to NSHPT.

Chapter.  8834 words.  Illustrated.

Subjects: Endocrinology and Diabetes

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.